Literature DB >> 21544958

Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases.

Stephen Shuttleworth1, Franck Silva, Cyrille Tomassi, Alexander Cecil, Thomas Hill, Helen Rogers, Paul Townsend.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 21544958     DOI： 10.1016/s0079-6468(09)04803-6

Source DB:  PubMed          Journal:  Prog Med Chem        ISSN： 0079-6468


× No keyword cloud information.
  2 in total

Review 1.  PI3K: from the bench to the clinic and back.

Authors:  Bart Vanhaesebroeck; Peter K Vogt; Christian Rommel
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 2.  Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

Authors:  S J Shuttleworth; F A Silva; A R L Cecil; C D Tomassi; T J Hill; F I Raynaud; P A Clarke; P Workman
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.